Xiaotu Ma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiaotu Ma has a total of 626 co-authors. Here are the top co-authors by number of shared publications:
- Jinghui Zhang
St Jude Children's Research Hospital, Memphis, TN
50 shared publications - John Easton
St. Jude Children’s Research Hospital 2 Department of Computational Biology Memphis, Tennessee
41 shared publications - Jeffery M. Klco
Department of Pathology, St. Jude Children’s Research Hospital, Memphis, USA
28 shared publications - Heather L. Mulder
St. Jude Children’s Research Hospital 2 Department of Computational Biology Memphis, Tennessee
25 shared publications - Sivaraman Natarajan
Department of Computational Biology, St. Jude Children’s Research Hospital, Memphis, USA
25 shared publications - Charles G. Mullighan
St Jude Children's Research Hospital, Memphis, Tennessee, United States
23 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by American Society of Hematology in Blood
Identifying novel genomic alterations in relapsed childhood B-ALL: a report from the Children's Oncology Group
Relapsed B-acute lymphoblastic leukemia (B-ALL) generally occurs due to the emergence of subclones resistant to therapy, leading to poor outcome. Here, we describe novel genomic alterations responsible for therapeutic resistance at a subtype level in a clinical trial (AALL1331) which randomized patients to blinatumomab and chemotherapy versus chemotherapy alone. We performed whole-genome and transcriptome sequencing on 288 patients (183 diagnosis/first relapse/germline trios and 105 additional patients with first-relapse samples) and analyzed 41 second-relapse samples. For ETV6::RUNX1, we showed that cases with gain of the fusion allele or with fusion transcript involving exon 5 of ETV6 and exon 4 of RUNX1 (E5-E4) had a higher risk of first relapse than cases with E5-E3. For the hyperdiploid subtype, we demonstrated that low modal chromosomal numbers (51-52) were more prone to first relapse than those with ≥53 chromosomes, with an additive effect of CREBBP mutations. We showed enrichment of IKZF1 alterations in the Philadelphia-like subtype and that NSD2 E1099K was commonly associated with relapse in TCF3::PBX1. Together, these new features accounted for 30% (n=55) of first relapses. Intriguingly, ~3% of relapses are related to secondary B-ALL or germline predisposition. We also compared genomic alterations at diagnosis and first relapse in relation to second relapse status in randomized patients, with TCF3::PBX1/NT5C2 linked to worse outcomes regardless of randomized arm. Together, our findings provide novel insights into the genomics of relapsed childhood B-ALL as well as in the context of blinatumomab therapy. This trial was registered at www.clinicaltrials.gov as # NCT0201853.
- 2 November 2026
- Published by American Society of Hematology in Blood
Open AccessIdentifying novel genomic alterations in relapsed childhood B-ALL: a report from the Children's Oncology Group
Relapsed B-acute lymphoblastic leukemia (B-ALL) generally occurs due to the emergence of subclones resistant to therapy, leading to poor outcome. Here, we describe novel genomic alterations responsible for therapeutic resistance at a subtype level in a clinical trial (AALL1331) which randomized patients to blinatumomab and chemotherapy versus chemotherapy alone. We performed whole-genome and transcriptome sequencing on 288 patients (183 diagnosis/first relapse/germline trios and 105 additional patients with first-relapse samples) and analyzed 41 second-relapse samples. For ETV6::RUNX1, we showed that cases with gain of the fusion allele or with fusion transcript involving exon 5 of ETV6 and exon 4 of RUNX1 (E5-E4) had a higher risk of first relapse than cases with E5-E3. For the hyperdiploid subtype, we demonstrated that low modal chromosomal numbers (51-52) were more prone to first relapse than those with ≥53 chromosomes, with an additive effect of CREBBP mutations. We showed enrichment of IKZF1 alterations in the Philadelphia-like subtype and that NSD2 E1099K was commonly associated with relapse in TCF3::PBX1. Together, these new features accounted for 30% (n=55) of first relapses. Intriguingly, ~3% of relapses are related to secondary B-ALL or germline predisposition. We also compared genomic alterations at diagnosis and first relapse in relation to second relapse status in randomized patients, with TCF3::PBX1/NT5C2 linked to worse outcomes regardless of randomized arm. Together, our findings provide novel insights into the genomics of relapsed childhood B-ALL as well as in the context of blinatumomab therapy. This trial was registered at www.clinicaltrials.gov as # NCT0201853.
- Open Access
- 20 October 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (11)
Dysregulated AKT signaling reprograms osteosarcoma to drive selective reliance on EP300
Cancers depend on transcriptional control to maintain the malignant cell state. EP300 and CBP are paralogous master epigenetic enzymes that control normal and malignant transcription. Using a cancer-wide integrative chemical-genetic analysis, we demonstrate enhanced dependency on EP300, compared with CBP, in cell lines from most cancer lineages, including lethal osteosarcoma (OS). Using a selective EP300 degrader (JQAD1), we identify that a genetically defined subgroup of OS with dysregulation of the PI3K–AKT–mTOR pathway is genetically and chemically sensitive to loss of EP300. Activated AKT promotes sensitivity to JQAD1, driven by relocalization of EP300, CBP and H3K27ac to genetic subtype-enriched dependency loci. AKT inhibition combines with JQAD1 to synergistically suppress the growth of AKT-dysregulated OS cells in vitro and in orthotopic xenografts. These observations extend across >850 cancer cell lines, where synergy is predicted by elevated protein synthetic rates. These findings reveal determinants of EP300 degrader function in OS and provide a foundation for co-targeting EP300 and AKT in cancers with enhanced protein translation.
- 20 October 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (11)
Open AccessDysregulated AKT signaling reprograms osteosarcoma to drive selective reliance on EP300
Cancers depend on transcriptional control to maintain the malignant cell state. EP300 and CBP are paralogous master epigenetic enzymes that control normal and malignant transcription. Using a cancer-wide integrative chemical-genetic analysis, we demonstrate enhanced dependency on EP300, compared with CBP, in cell lines from most cancer lineages, including lethal osteosarcoma (OS). Using a selective EP300 degrader (JQAD1), we identify that a genetically defined subgroup of OS with dysregulation of the PI3K–AKT–mTOR pathway is genetically and chemically sensitive to loss of EP300. Activated AKT promotes sensitivity to JQAD1, driven by relocalization of EP300, CBP and H3K27ac to genetic subtype-enriched dependency loci. AKT inhibition combines with JQAD1 to synergistically suppress the growth of AKT-dysregulated OS cells in vitro and in orthotopic xenografts. These observations extend across >850 cancer cell lines, where synergy is predicted by elevated protein synthetic rates. These findings reveal determinants of EP300 degrader function in OS and provide a foundation for co-targeting EP300 and AKT in cancers with enhanced protein translation.
- Open Access
- 2 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (40)
Tumor gasdermin E acts as a rheostat to limit apoptotic cell survival and mutagenesis in anticancer immune environments
Recent studies have described an ability of cancer cells to survive engagement of apoptotic pathways following chemical and therapeutic insults, challenging the prevailing model that caspase activation inevitably leads to cellular demise. Gasdermin E (GSDME), whose expression is frequently down-regulated or silenced in many tumors and tumor-derived cell lines, is a putative tumor suppressor capable of facilitating the induction of antitumor immunity. We found that GSDME expression precluded high caspase activity before cellular membrane rupture downstream of chemical and immune-mediated insults, and its absence allowed for enhanced activities downstream of caspase activation, including the DNA-damaging effects of caspase-activated deoxyribonuclease. Loss of GSDME allowed cells that had sustained DNA damage to survive, resulting in development and propagation of mutated clones. We conclude that GSDME functions as a key rheostat for determining cell death outcomes by tuning the tolerance to the activities of caspases and their substrates during apoptosis. In analyzing solid tumors in The Cancer Genome Atlas, we found that tumor mutational burden was higher in tumors with low GSDME expression and high immune signatures, supporting the possibility that the effects we describe affect tumor mutation in response to immune assault.
- 2 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (40)
Open AccessTumor gasdermin E acts as a rheostat to limit apoptotic cell survival and mutagenesis in anticancer immune environments
Recent studies have described an ability of cancer cells to survive engagement of apoptotic pathways following chemical and therapeutic insults, challenging the prevailing model that caspase activation inevitably leads to cellular demise. Gasdermin E (GSDME), whose expression is frequently down-regulated or silenced in many tumors and tumor-derived cell lines, is a putative tumor suppressor capable of facilitating the induction of antitumor immunity. We found that GSDME expression precluded high caspase activity before cellular membrane rupture downstream of chemical and immune-mediated insults, and its absence allowed for enhanced activities downstream of caspase activation, including the DNA-damaging effects of caspase-activated deoxyribonuclease. Loss of GSDME allowed cells that had sustained DNA damage to survive, resulting in development and propagation of mutated clones. We conclude that GSDME functions as a key rheostat for determining cell death outcomes by tuning the tolerance to the activities of caspases and their substrates during apoptosis. In analyzing solid tumors in The Cancer Genome Atlas, we found that tumor mutational burden was higher in tumors with low GSDME expression and high immune signatures, supporting the possibility that the effects we describe affect tumor mutation in response to immune assault.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Data from Therapy-Related Mutational Signatures in Subsequent Neoplasms among Survivors of Childhood Cancer
Childhood cancer survivors have a heightened risk of developing subsequent neoplasms (SN) related to therapy. We analyzed whole-genome, exome, and RNA sequencing of 200 breast, meningioma, and thyroid SNs, which developed a median of 26.4 years after childhood cancer, among 160 survivors. Meningioma and thyroid SNs were enriched for driver gene rearrangements compared with de novo tumors, including NF2-disrupting alterations and kinase fusions potentially induced by radiation. Radiation correlated with increased insertion–deletion signature ID5. Nitrogen mustard treatment correlated with elevated “flat” signature SBS5 in breast and meningioma SNs; in vitro, these agents caused an unresolved flat signature associated with multiple flat signatures from the Catalogue of Somatic Mutations in Cancer. In meningioma, platinum therapy correlated with NF2 splice-site variants. Analysis of 19 multisample survivors revealed intrapatient heterogeneity in meningioma, including clonally independent tumors. These results demonstrate the long-term impact of childhood cancer treatment on the genomes of SNs developing in adulthood, which may guide SN treatment and prevention. Significance:This represents the most comprehensive genomic characterization of SNs from childhood cancer survivors to date, revealing the mutagenic impact of multiple therapies on the SN genome, including the potential impact of nitrogen mustards such as cyclophosphamide. These results may guide the optimization of future cancer treatment regimens to prevent SN development.See related commentary by Bertrums and van Boxtel, p. 1483
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Therapy-Related Mutational Signatures in Subsequent Neoplasms among Survivors of Childhood Cancer
Childhood cancer survivors have a heightened risk of developing subsequent neoplasms (SN) related to therapy. We analyzed whole-genome, exome, and RNA sequencing of 200 breast, meningioma, and thyroid SNs, which developed a median of 26.4 years after childhood cancer, among 160 survivors. Meningioma and thyroid SNs were enriched for driver gene rearrangements compared with de novo tumors, including NF2-disrupting alterations and kinase fusions potentially induced by radiation. Radiation correlated with increased insertion–deletion signature ID5. Nitrogen mustard treatment correlated with elevated “flat” signature SBS5 in breast and meningioma SNs; in vitro, these agents caused an unresolved flat signature associated with multiple flat signatures from the Catalogue of Somatic Mutations in Cancer. In meningioma, platinum therapy correlated with NF2 splice-site variants. Analysis of 19 multisample survivors revealed intrapatient heterogeneity in meningioma, including clonally independent tumors. These results demonstrate the long-term impact of childhood cancer treatment on the genomes of SNs developing in adulthood, which may guide SN treatment and prevention. Significance:This represents the most comprehensive genomic characterization of SNs from childhood cancer survivors to date, revealing the mutagenic impact of multiple therapies on the SN genome, including the potential impact of nitrogen mustards such as cyclophosphamide. These results may guide the optimization of future cancer treatment regimens to prevent SN development.See related commentary by Bertrums and van Boxtel, p. 1483
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S22 from Therapy-Related Mutational Signatures in Subsequent Neoplasms among Survivors of Childhood Cancer
Supplementary Figure S1 shows SN sample exclusion, sequencing coverage, and sequencing types. Supplementary Figure S2 shows filtering approaches for exome FFPE artefacts in 33 pediatric tumors with matched FFPE vs. fresh-frozen data. Supplementary Figure S3 shows the correlation between SNV burden in SN exome vs. WGS data. Supplementary Figure S4 shows TCGA exome SNV and indel burden analysis for de novo cancer cohorts. Supplementary Figure S5 shows coverage data and absence of significant coverage effects on mutation burdens. Supplementary Figure S6 shows a comparison of SNV, indel, and SV burdens in 8 ovarian tumors with matched FFPE vs. fresh-frozen data. Supplementary Figure S7 shows de novo signature extraction data for SNV and indel signatures. Supplementary Figure S8 shows SNV signature data for thyroid SNs and dose-response analysis in meningioma SNs. Supplementary Figure S9 shows drug dose response curves in MCF10A cells. Supplementary Figure S10 shows the cisplatin signature in MCF10A cells. Supplementary Figure S11 shows additional details of experimental drug signatures and comparison signatures from other experimental studies. Supplementary Figure S12 shows the effects of simulated 4-OH-cyclophosphamide treatment on SNV signatures in patient tumors. Supplementary Figure S13 shows doublet signatures in SNs. Supplementary Figure S14 shows meningioma SN copy profiles. Supplementary Figure S15 shows details of functional NF2 splicing assays. Supplementary Figure S16 shows how probabilities were predicted for NF2 variant induction by platinum signatures. Supplementary Figure S17 shows breast SN copy profiles. Supplementary Figure S18 shows clonal evolution trees for breast, meningioma, and thyroid SNs. Supplementary Figure S19 shows details of clonal evolution in breast SNs. Supplementary Figure S20 shows details of clonal evolution in meningioma SNs. Supplementary Figure S21 shows details of clonal evolution in thyroid SNs. Supplementary Figure S22 shows selection of high-quality WGS samples for mutational signature analysis based on coverage breadth
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S22 from Therapy-Related Mutational Signatures in Subsequent Neoplasms among Survivors of Childhood Cancer
Supplementary Figure S1 shows SN sample exclusion, sequencing coverage, and sequencing types. Supplementary Figure S2 shows filtering approaches for exome FFPE artefacts in 33 pediatric tumors with matched FFPE vs. fresh-frozen data. Supplementary Figure S3 shows the correlation between SNV burden in SN exome vs. WGS data. Supplementary Figure S4 shows TCGA exome SNV and indel burden analysis for de novo cancer cohorts. Supplementary Figure S5 shows coverage data and absence of significant coverage effects on mutation burdens. Supplementary Figure S6 shows a comparison of SNV, indel, and SV burdens in 8 ovarian tumors with matched FFPE vs. fresh-frozen data. Supplementary Figure S7 shows de novo signature extraction data for SNV and indel signatures. Supplementary Figure S8 shows SNV signature data for thyroid SNs and dose-response analysis in meningioma SNs. Supplementary Figure S9 shows drug dose response curves in MCF10A cells. Supplementary Figure S10 shows the cisplatin signature in MCF10A cells. Supplementary Figure S11 shows additional details of experimental drug signatures and comparison signatures from other experimental studies. Supplementary Figure S12 shows the effects of simulated 4-OH-cyclophosphamide treatment on SNV signatures in patient tumors. Supplementary Figure S13 shows doublet signatures in SNs. Supplementary Figure S14 shows meningioma SN copy profiles. Supplementary Figure S15 shows details of functional NF2 splicing assays. Supplementary Figure S16 shows how probabilities were predicted for NF2 variant induction by platinum signatures. Supplementary Figure S17 shows breast SN copy profiles. Supplementary Figure S18 shows clonal evolution trees for breast, meningioma, and thyroid SNs. Supplementary Figure S19 shows details of clonal evolution in breast SNs. Supplementary Figure S20 shows details of clonal evolution in meningioma SNs. Supplementary Figure S21 shows details of clonal evolution in thyroid SNs. Supplementary Figure S22 shows selection of high-quality WGS samples for mutational signature analysis based on coverage breadth
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S26 from Therapy-Related Mutational Signatures in Subsequent Neoplasms among Survivors of Childhood Cancer
Supplementary Table S1 shows SN sample clinical variables and metadata. Supplementary Table S2 shows a comparison of variables between good-quality vs. excluded samples. Supplementary Table S3 shows a summary of prior treatments across SN patients. Supplementary Table S4 shows a summary of original childhood cancer diagnoses for SN patients. Supplementary Table S5 shows metadata for 33 pediatric cancers with matched FFPE and fresh-frozen exome data. Supplementary Table S6 shows a list of coding-region somatic SNVs used for mutation burden analysis. Supplementary Table S7 shows multivariable analysis comparing SNV burdens between cohorts. Supplementary Table S8 shows multivariable analysis comparing age between cohorts. Supplementary Table S9 shows multivariable analysis comparing SNV burdens between thyroid cancer cohorts among samples with coverage below 100x. Supplementary Table S10 shows cancer-predisposing germline alterations among SN patients. Supplementary Table S11 shows a list of coding-region somatic indels used for mutation burden analysis. Supplementary Table S12 shows multivariable analysis comparing indel burdens between cohorts. Supplementary Table S13 shows SNV signature levels among SNs. Supplementary Table S14 shows multivariable analysis comparing SBS5 burdens in breast SNs stratified by prior treatment. Supplementary Table S15 shows multivariable analysis comparing SBS5 burdens in meningioma SNs stratified by prior treatment. Supplementary Table S16 shows multivariable analysis testing SBS5-cyclophosphamide dose-response relationship in meningioma SNs. Supplementary Table S17 shows variation in cyclophosphamide-containing regimens among meningioma SNs. Supplementary Table S18 shows indel signature levels among SNs. Supplementary Table S19 shows multivariable analysis testing ID5-radiation dose-response relationship in each SN type. Supplementary Table S20 shows multivariable analysis testing ID5-radiation dose-response relationship with all 3 SN types combined. Supplementary Table S21 shows NF2-disrupting structural variants detected in meningioma SNs. Supplementary Table S22 shows multivariable analysis comparing driver alteration frequency between meningioma cohorts. Supplementary Table S23 shows driver fusions in thyroid SNs. Supplementary Table S24 shows multivariable analysis comparing mutation group frequency between thyroid cancer cohorts. Supplementary Table S25 shows multivariable analysis comparing driver alteration frequency between thyroid cancer cohorts. Supplementary Table S26 shows multivariable analysis comparing driver alteration frequency between breast cancer cohorts
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S26 from Therapy-Related Mutational Signatures in Subsequent Neoplasms among Survivors of Childhood Cancer
Supplementary Table S1 shows SN sample clinical variables and metadata. Supplementary Table S2 shows a comparison of variables between good-quality vs. excluded samples. Supplementary Table S3 shows a summary of prior treatments across SN patients. Supplementary Table S4 shows a summary of original childhood cancer diagnoses for SN patients. Supplementary Table S5 shows metadata for 33 pediatric cancers with matched FFPE and fresh-frozen exome data. Supplementary Table S6 shows a list of coding-region somatic SNVs used for mutation burden analysis. Supplementary Table S7 shows multivariable analysis comparing SNV burdens between cohorts. Supplementary Table S8 shows multivariable analysis comparing age between cohorts. Supplementary Table S9 shows multivariable analysis comparing SNV burdens between thyroid cancer cohorts among samples with coverage below 100x. Supplementary Table S10 shows cancer-predisposing germline alterations among SN patients. Supplementary Table S11 shows a list of coding-region somatic indels used for mutation burden analysis. Supplementary Table S12 shows multivariable analysis comparing indel burdens between cohorts. Supplementary Table S13 shows SNV signature levels among SNs. Supplementary Table S14 shows multivariable analysis comparing SBS5 burdens in breast SNs stratified by prior treatment. Supplementary Table S15 shows multivariable analysis comparing SBS5 burdens in meningioma SNs stratified by prior treatment. Supplementary Table S16 shows multivariable analysis testing SBS5-cyclophosphamide dose-response relationship in meningioma SNs. Supplementary Table S17 shows variation in cyclophosphamide-containing regimens among meningioma SNs. Supplementary Table S18 shows indel signature levels among SNs. Supplementary Table S19 shows multivariable analysis testing ID5-radiation dose-response relationship in each SN type. Supplementary Table S20 shows multivariable analysis testing ID5-radiation dose-response relationship with all 3 SN types combined. Supplementary Table S21 shows NF2-disrupting structural variants detected in meningioma SNs. Supplementary Table S22 shows multivariable analysis comparing driver alteration frequency between meningioma cohorts. Supplementary Table S23 shows driver fusions in thyroid SNs. Supplementary Table S24 shows multivariable analysis comparing mutation group frequency between thyroid cancer cohorts. Supplementary Table S25 shows multivariable analysis comparing driver alteration frequency between thyroid cancer cohorts. Supplementary Table S26 shows multivariable analysis comparing driver alteration frequency between breast cancer cohorts
- Open Access
- 21 July 2026
- Published by Springer Nature in Leukemia
- Vol. 40 (9) , 2018-2026
The effect of cohesin mutations on HLA-class II expression in the myeloid leukemia of Down syndrome
Children with Down syndrome (DS) frequently develop transient abnormal myelopoiesis that can evolve to the myeloid leukemia of DS (ML-DS). TAM spontaneously resolves in most cases but progresses to ML-DS with additional mutations, most commonly in the cohesin complex. However, the mechanisms by which these alterations promote leukemia are unknown. We leveraged the RAD21-mutant CMY cell line and RAD21-corrected CMY isogenic clones, as well as patient data, to investigate the effect of cohesin mutations during leukemia progression. RNA-sequencing revealed that HLA-class II genes were significantly down-regulated with cohesin mutations. Furthermore, HLA-DR was found to be lower in ML-DS relative to TAM, and these decreased levels were associated with increased risk of leukemia progression. Multi-omic analyses revealed that haploinsufficiency of RAD21 altered chromatin accessibility and impaired the occupancy of GATA1s and CIITA, the master regulator of HLA-class II gene expression. Chromatin binding of CIITA was increased with RAD21 correction, providing a mechanism by which restoration of cohesin improves HLA-class II expression. Finally, decreased levels of RAD21 or STAG2 expression in other subtypes of AML also exhibited reduced expression of HLA-class II genes. Thus, cohesin may contribute to leukemia by altering HLA-class II gene expression.
- 21 July 2026
- Published by Springer Nature in Leukemia
- Vol. 40 (9) , 2018-2026
Open AccessThe effect of cohesin mutations on HLA-class II expression in the myeloid leukemia of Down syndrome
Children with Down syndrome (DS) frequently develop transient abnormal myelopoiesis that can evolve to the myeloid leukemia of DS (ML-DS). TAM spontaneously resolves in most cases but progresses to ML-DS with additional mutations, most commonly in the cohesin complex. However, the mechanisms by which these alterations promote leukemia are unknown. We leveraged the RAD21-mutant CMY cell line and RAD21-corrected CMY isogenic clones, as well as patient data, to investigate the effect of cohesin mutations during leukemia progression. RNA-sequencing revealed that HLA-class II genes were significantly down-regulated with cohesin mutations. Furthermore, HLA-DR was found to be lower in ML-DS relative to TAM, and these decreased levels were associated with increased risk of leukemia progression. Multi-omic analyses revealed that haploinsufficiency of RAD21 altered chromatin accessibility and impaired the occupancy of GATA1s and CIITA, the master regulator of HLA-class II gene expression. Chromatin binding of CIITA was increased with RAD21 correction, providing a mechanism by which restoration of cohesin improves HLA-class II expression. Finally, decreased levels of RAD21 or STAG2 expression in other subtypes of AML also exhibited reduced expression of HLA-class II genes. Thus, cohesin may contribute to leukemia by altering HLA-class II gene expression.
- Open Access
- 24 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (8) , OF1-OF21
Therapy-Related Mutational Signatures in Subsequent Neoplasms among Survivors of Childhood Cancer
Childhood cancer survivors have a heightened risk of developing subsequent neoplasms (SN) related to therapy. We analyzed whole-genome, exome, and RNA sequencing of 200 breast, meningioma, and thyroid SNs, which developed a median of 26.4 years after childhood cancer, among 160 survivors. Meningioma and thyroid SNs were enriched for driver gene rearrangements compared with de novo tumors, including NF2-disrupting alterations and kinase fusions potentially induced by radiation. Radiation correlated with increased insertion–deletion signature ID5. Nitrogen mustard treatment correlated with elevated “flat” signature SBS5 in breast and meningioma SNs; in vitro, these agents caused an unresolved flat signature associated with multiple flat signatures from the Catalogue of Somatic Mutations in Cancer. In meningioma, platinum therapy correlated with NF2 splice-site variants. Analysis of 19 multisample survivors revealed intrapatient heterogeneity in meningioma, including clonally independent tumors. These results demonstrate the long-term impact of childhood cancer treatment on the genomes of SNs developing in adulthood, which may guide SN treatment and prevention. Significance: This represents the most comprehensive genomic characterization of SNs from childhood cancer survivors to date, revealing the mutagenic impact of multiple therapies on the SN genome, including the potential impact of nitrogen mustards such as cyclophosphamide. These results may guide the optimization of future cancer treatment regimens to prevent SN development.
- 24 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (8) , OF1-OF21
Open AccessTherapy-Related Mutational Signatures in Subsequent Neoplasms among Survivors of Childhood Cancer
Childhood cancer survivors have a heightened risk of developing subsequent neoplasms (SN) related to therapy. We analyzed whole-genome, exome, and RNA sequencing of 200 breast, meningioma, and thyroid SNs, which developed a median of 26.4 years after childhood cancer, among 160 survivors. Meningioma and thyroid SNs were enriched for driver gene rearrangements compared with de novo tumors, including NF2-disrupting alterations and kinase fusions potentially induced by radiation. Radiation correlated with increased insertion–deletion signature ID5. Nitrogen mustard treatment correlated with elevated “flat” signature SBS5 in breast and meningioma SNs; in vitro, these agents caused an unresolved flat signature associated with multiple flat signatures from the Catalogue of Somatic Mutations in Cancer. In meningioma, platinum therapy correlated with NF2 splice-site variants. Analysis of 19 multisample survivors revealed intrapatient heterogeneity in meningioma, including clonally independent tumors. These results demonstrate the long-term impact of childhood cancer treatment on the genomes of SNs developing in adulthood, which may guide SN treatment and prevention. Significance: This represents the most comprehensive genomic characterization of SNs from childhood cancer survivors to date, revealing the mutagenic impact of multiple therapies on the SN genome, including the potential impact of nitrogen mustards such as cyclophosphamide. These results may guide the optimization of future cancer treatment regimens to prevent SN development.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Conditional Activation of c-MYC in Distinct Catecholaminergic Cells Drives Development of Neuroblastoma or Somatostatinoma
GSEA results for c-MYC PNET and c-MYC neuroblastoma
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Conditional Activation of c-MYC in Distinct Catecholaminergic Cells Drives Development of Neuroblastoma or Somatostatinoma
GSEA results for c-MYC PNET and c-MYC neuroblastoma
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Conditional Activation of c-MYC in Distinct Catecholaminergic Cells Drives Development of Neuroblastoma or Somatostatinoma
Differentially expressed genes in c-MYC- and MYCN-driven neuroblastomas
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Conditional Activation of c-MYC in Distinct Catecholaminergic Cells Drives Development of Neuroblastoma or Somatostatinoma
Differentially expressed genes in c-MYC- and MYCN-driven neuroblastomas